David Moreno-Ajona

List of Publications by Year
in descending order

282 papers	24,886 citations	9784 73 h-index	7744 150 g-index
285 all docs	285 docs citations	285 times ranked	8432 citing authors

#	Article	IF	Citations
1	A novel maneuver for diagnosis and treatment of torsional-vertical down beating positioning nystagmus: anterior canal and apogeotropic posterior canal BPPV. Brazilian Journal of Otorhinolaryngology, 2022, 88, 708-716.	1.0	5
2	Neuronal nitric oxide synthase regulates regional brain perfusion in healthy humans. Cardiovascular Research, 2022, 118, 1321-1329.	3.8	11
3	Evaluation of treatment response and symptom progression in 400 patients with visual snow syndrome. British Journal of Ophthalmology, 2022, 106, 1318-1324.	3.9	23
4	The selective 5â€HT_{1F} receptor agonist lasmiditan inhibits trigeminal nociceptive processing: Implications for migraine and cluster headache. British Journal of Pharmacology, 2022, 179, 358-370.	5.4	17
5	Areas of cerebral blood flow changes on arterial spin labelling with the use of symmetric template during nitroglycerin triggered cluster headache attacks. NeuroImage: Clinical, 2022, 33, 102920.	2.7	1
6	Cranial autonomic symptoms: prevalence, phenotype and laterality in migraine and two potentially new symptoms. Journal of Headache and Pain, 2022, 23, 18.	6.0	11
7	Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurology, The, 2022, 21, 284-294.	10.2	59
8	Synchronized refixation saccades in enhanced VVOR test. A new application for PR score. Journal of Vestibular Research: Equilibrium and Orientation, 2022, 32, 443-451.	2.0	1
9	Speech Recognition During Follow-Up of Patients with MÃ©niÃ¨reâ€™s Disease: What Are We Missing?. , 2022, 18, 14-19.		2
10	Devices for Episodic Migraine: Past, Present, and Future. Current Pain and Headache Reports, 2022, 26, 259-265.	2.9	3
11	Low-Dose Intratympanic Gentamicin for Unilateral MÃ©niÃ¨reâ€˜s Disease: Accuracy of Early Vestibulo-Ocular Reflex Gain Reduction in Predicting Long-Term Clinical Outcome. Frontiers in Neurology, 2022, 13, 808570.	2.4	0
12	New Generation Gepants: Migraine Acute and Preventive Medications. Journal of Clinical Medicine, 2022, 11, 1656.	2.4	33
13	Menstruation-related hypersomnia. Electroencephalographic and actigraphic correlation in an underrecognized neuropsychiatric disorder. Sleep Medicine, 2022, 91, 93-95.	1.6	1
14	A Prospective Real-World Study Exploring Associations Between Passively Collected Tracker Data and Headache Burden Among Individuals with Tension-Type Headache and Migraine. Pain and Therapy, 2022, 11, 153-170.	3.2	2
15	Skull Vibration-Induced Nystagmus and High Frequency Ocular Vestibular-Evoked Myogenic Potentials in Superior Canal Dehiscence. Audiology Research, 2022, 12, 202-211.	1.8	5
16	Erenumab in chronic migraine: Experience from a UK tertiary centre and comparison with other realâ€world evidence. European Journal of Neurology, 2022, 29, 2473-2480.	3.3	9
17	Evaluating the clinical utility of the patientâ€identified most bothersome symptom measure from PROMISEâ€2 for research in migraine prevention. Headache, 2022, 62, 690-699.	3.9	6
18	Case Report: Transformation of Visual Snow Syndrome From Episodic to Chronic Associated With Acute Cerebellar Infarct. Frontiers in Neurology, 2022, 13, 811490.	2.4	9

#	Article	IF	Citations
19	Endolymphatic hydrops in the unaffected ear of patients with unilateral MÃ©niÃ¨reâ€™s disease. European Archives of Oto-Rhino-Laryngology, 2022, 279, 5591-5600.	1.6	5
20	Defective Î±â€tectorin may involve tectorial membrane in familial Meniere disease. Clinical and Translational Medicine, 2022, 12, .	4.0	11
21	KCl-induced repetitive cortical spreading depression inhibiting trigeminal neuronal firing is mediated by 5-HT_{1B/1D} and opioid receptors. Cephalalgia, 2022, 42, 1339-1348.	3.9	2
22	VEMPs and Dysautonomia Assessment in Definite Cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): a Case Series Study. Cerebellum, 2021, 20, 717-723.	2.5	13
23	In Response to A New and Faster Method to Assess Vestibular Compensation: A <scp>Crossâ€Sectional</scp><scp>Study</scp>. Laryngoscope, 2021, 131, E582.	2.0	2
24	Headache research in 2020: disrupting and improving practice. Lancet Neurology, The, 2021, 20, 7-8.	10.2	3
25	Eptinezumab for the preventive treatment of migraine. Pain Management, 2021, 11, 113-121.	1.5	7
26	Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet, The, 2021, 397, 51-60.	13.7	178
27	Are some patient-perceived migraine triggers simply early manifestations of the attack?. Journal of Neurology, 2021, 268, 1885-1893.	3.6	34
28	Emerging Targets for Migraine Treatment. Neurology India, 2021, 69, 98.	0.4	5
29	Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?. Neurology India, 2021, 69, 59.	0.4	1
30	The migraine postdrome: Spontaneous and triggered phenotypes. Cephalalgia, 2021, 41, 721-730.	3.9	18
31	Disrupted connectivity within visual, attentional and salience networks in the visual snow syndrome. Human Brain Mapping, 2021, 42, 2032-2044.	3.6	31
32	Comprehensive clinical phenotyping of nitroglycerin infusion induced cluster headache attacks. Cephalalgia, 2021, 41, 913-933.	3.9	15
33	Targets for migraine treatment: beyond calcitonin gene-related peptide. Current Opinion in Neurology, 2021, 34, 363-372.	3.6	11
34	Cluster headache pathophysiology â€" insights from current and emerging treatments. Nature Reviews Neurology, 2021, 17, 308-324.	10.1	45
35	Exploding head syndrome (a.k.a. episodic cranial sensory shock) responds to singleâ€pulse transcranial magnetic stimulation. European Journal of Neurology, 2021, 28, 1432-1433.	3.3	1
36	Long-term Efficacy and Safety of Erenumab. Neurology, 2021, 96, .	1.1	25

#	Article	IF	Citations
37	Migraine: disease characterisation, biomarkers, and precision medicine. Lancet, The, 2021, 397, 1496-1504.	13.7	141
38	21st century headache: mapping new territory. Journal of Headache and Pain, 2021, 22, 19.	6.0	19
39	Indomethacinâ€responsive headachesâ€"A narrative review. Headache, 2021, 61, 700-714.	3.9	20
40	Endolymphatic Hydrops in Fluctuating Hearing Loss and Recurrent Vertigo. Frontiers in Surgery, 2021, 8, 673847.	1.4	8
41	Migraine Is More Than Just Headache: Is the Link to Chronic Fatigue and Mood Disorders Simply Due to Shared Biological Systems?. Frontiers in Human Neuroscience, 2021, 15, 646692.	2.0	22
42	Localised increase in regional cerebral perfusion in patients with visual snow syndrome: a pseudo-continuous arterial spin labelling study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 918-926.	1.9	17
43	Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine, 2021, 385, 695-706.	27.0	126
44	Characterization of opioidergic mechanisms related to the anti-migraine effect of vagus nerve stimulation. Neuropharmacology, 2021, 195, 108375.	4.1	11
45	Multidisciplinary headache clinic-impact of a new model for headache care in Dubai. Clinical Neurology and Neurosurgery, 2021, 208, 106845.	1.4	1
46	Was it something I ate? Understanding the bidirectional interaction of migraine and appetite neural circuits. Brain Research, 2021, 1770, 147629.	2.2	16
47	Differential actions of indomethacin: clinical relevance in headache. Pain, 2021, 162, 591-599.	4.2	17
48	Therapeutic targeting of nitroglycerin-mediated trigeminovascular neuronal hypersensitivity predicts clinical outcomes of migraine abortives. Pain, 2021, 162, 1567-1577.	4.2	12
49	Integrating headache trigger management strategies into cognitive-behavioral therapy: A randomized controlled trial.. Health Psychology, 2021, 40, 674-685.	1.6	10
50	Dissociated vestibular test results (caloric and vHIT) in patients with Menereâ€™s disease are not due to velocity storage malfunction. Hearing, Balance and Communication, 2020, 18, 136-142.	0.4	2
51	Bilateral Vestibular Hypofunction in the Time of the Video Head Impulse Test. Audiology and Neuro-Otology, 2020, 25, 72-78.	1.3	4
52	Recent Advances in the Management of Cluster Headache. Current Treatment Options in Neurology, 2020, 22, 1.	1.8	2
53	Primary cough headache treated with non-invasive vagal nerve stimulation. Neurology, 2020, 95, 593-594.	1.1	9
54	Occipital cortex and cerebellum gray matter changes in visual snow syndrome. Neurology, 2020, 95, e1792-e1799.	1.1	35

#	Article	IF	Citations
55	Differential medication overuse risk of novel anti-migraine therapeutics. Brain, 2020, 143, 2681-2688.	7.6	37
56	Alterations in Functional Connectivity During Different Phases of the Triggered Migraine Attack. Headache, 2020, 60, 1244-1258.	3.9	20
57	18F-FDG-PET Imaging Patterns in Autoimmune Encephalitis: Impact of Image Analysis on the Results. Diagnostics, 2020, 10, 356.	2.6	36
58	Testing rimegepant for migraineâ€"time to revise the trial design? â€" Authors' reply. Lancet, The, 2020, 395, 1901-1902.	13.7	1
59	Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Medicine in Drug Discovery, 2020, 7, 100053.	4.5	15
60	Perceptions, experiences, and understandings of cluster headache among GPs and neurologists: a qualitative study. British Journal of General Practice, 2020, 70, e514-e522.	1.4	6
61	An Update on Imaging in Idiopathic Intracranial Hypertension. Frontiers in Neurology, 2020, 11, 453.	2.4	9
62	Insular and occipital changes in visual snow syndrome: a BOLD fMRI and MRS study. Annals of Clinical and Translational Neurology, 2020, 7, 296-306.	3.7	46
63	Structural and functional footprint of visual snow syndrome. Brain, 2020, 143, 1106-1113.	7.6	58
64	Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology, 2020, 94, e1365-e1377.	1.1	236
65	Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study. Cephalalgia, 2020, 40, 828-841.	3.9	28
66	One-year sustained efficacy of erenumab in episodic migraine. Neurology, 2020, 95, e469-e479.	1.1	41
67	PAC1 receptor blockade reduces central nociceptive activity: new approach for primary headache?. Pain, 2020, 161, 1670-1681.	4.2	39
68	A New and Faster Method to Assess Vestibular Compensation: A Crossâ€Sectional Study. Laryngoscope, 2020, 130, E911-E917.	2.0	13
69	Elevated circulating metalloproteinase 7 predicts recurrent cardiovascular events in patients with carotid stenosis: a prospective cohort study. BMC Cardiovascular Disorders, 2020, 20, 93.	1.7	5
70	Acidâ€sensing ion channel 3 blockade inhibits durovascular and nitric oxideâ€mediated trigeminal pain. British Journal of Pharmacology, 2020, 177, 2478-2486.	5.4	25
71	Visual snow syndrome. Neurology, 2020, 94, e564-e574.	1.1	80
72	CGRP pathway monoclonal antibodies for cluster headache. Expert Opinion on Biological Therapy, 2020, 20, 947-953.	3.1	13

#	Article	IF	Citations
73	Co-activation of rhythms during alpha band oscillations as an interictal biomarker of exploding head syndrome. Cephalalgia, 2020, 40, 949-958.	3.9	5
74	Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?. Current Opinion in Neurology, 2020, 33, 309-315.	3.6	62
75	Evolving options for the treatment of cluster headache. Current Opinion in Neurology, 2020, 33, 323-328.	3.6	4
76	The Association Between Parental Migraine and Infant Colic: A Crossâ€Sectional, Webâ€Based, U.S. Survey Study. Headache, 2019, 59, 988-1001.	3.9	14
77	Targeting CGRP and 5â€HT_{1F} Receptors for the Acute Therapy of Migraine: A Literature Review. Headache, 2019, 59, 3-19.	3.9	32
78	Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet, The, 2019, 394, 737-745.	13.7	236
79	Rimegepant, an Oral Calcitonin Geneâ€"Related Peptide Receptor Antagonist, for Migraine. New England Journal of Medicine, 2019, 381, 142-149.	27.0	235
80	Trial of Galcanezumab in Prevention of Episodic Cluster Headache. New England Journal of Medicine, 2019, 381, 132-141.	27.0	178
81	Managing cluster headache. Practical Neurology, 2019, 19, 521-528.	1.1	27
82	Pathophysiology of Migraine. Neurologic Clinics, 2019, 37, 651-671.	1.8	104
83	Aura and Head pain: relationship and gaps in the translational models. Journal of Headache and Pain, 2019, 20, 94.	6.0	38
84	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. Cephalalgia, 2019, 39, 1475-1487.	3.9	69
85	Recent Advances in Pharmacotherapy for Episodic Migraine. CNS Drugs, 2019, 33, 1053-1071.	5.9	26
86	Divergent influences of the locus coeruleus on migraine pathophysiology. Pain, 2019, 160, 385-394.	4.2	45
87	Classification of vestibular signs and examination techniques: Nystagmus and nystagmus-like movements. Journal of Vestibular Research: Equilibrium and Orientation, 2019, 29, 57-87.	2.0	79
88	Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia, 2019, 39, 1075-1085.	3.9	107
89	James W. Lance MD. Headache, 2019, 59, 825-827.	3.9	3
90	Primary headache disorders. Neurology: Clinical Practice, 2019, 9, 233-240.	1.6	25

#	Article	IF	Citations
91	Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain, 2019, 142, 1894-1904.	7.6	191
92	Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic. Journal of Headache and Pain, 2019, 20, 69.	6.0	11
93	Nâ€Methylâ€<scp>d</scp>â€aspartate receptor openâ€channel blockers memantine and magnesium modulate nociceptive trigeminovascular neurotransmission in rats. European Journal of Neuroscience, 2019, 50, 2847-2859.	2.6	15
94	Air and bone stimulation in vestibular evoked myogenic potentials in patients with unilateral MÃ©niÃ¨reâ€™s disease and in controls. Hearing, Balance and Communication, 2019, 17, 170-178.	0.4	3
95	The discovery and development of inhaled therapeutics for migraine. Expert Opinion on Drug Discovery, 2019, 14, 591-599.	5.0	4
96	Teaching NeuroImages: Greater occipital nerve injection. Neurology, 2019, 92, e746-e747.	1.1	1
97	Migraine progression in subgroups of migraine based on comorbidities. Neurology, 2019, 93, e2224-e2236.	1.1	60
98	Imaging the Visual Network in the Migraine Spectrum. Frontiers in Neurology, 2019, 10, 1325.	2.4	46
99	Facial solitary morphea profunda presenting with painful trigeminal neuropathy: A case report. Cephalalgia, 2019, 39, 564-568.	3.9	3
100	Endolymphatic hydrops severity in magnetic resonance imaging evidences disparate vestibular test results. Auris Nasus Larynx, 2019, 46, 210-217.	1.2	12
101	Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain, 2019, 142, 103-119.	7.6	62
102	Cortical abnormalities in episodic migraine: A multi-center 3T MRI study. Cephalalgia, 2019, 39, 665-673.	3.9	60
103	CGRP â€“ a target for acute therapy in migraine: Clinical data. Cephalalgia, 2019, 39, 420-427.	3.9	27
104	Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia, 2018, 38, 815-832.	3.9	245
105	A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia, 2018, 38, 1038-1048.	3.9	113
106	Migraine Therapy: Current Approaches and New Horizons. Neurotherapeutics, 2018, 15, 271-273.	4.4	12
107	Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs. Drugs, 2018, 78, 411-437.	10.9	54
108	Vestibuloâ€ocular reflex gain values in the suppression head impulse test of healthy subjects. Laryngoscope, 2018, 128, 2383-2389.	2.0	35

#	Article	IF	Citations
109	Case Report of the Safety Assessment of Transcranial Magnetic Stimulation Use in a Patient With Cardiac Pacemaker: To Pulse or Not to Pulse?. Headache, 2018, 58, 295-297.	3.9	5
110	Dissociated responses to caloric and head impulse stimulation in a case of isolated vestibule-lateral semicircular canal dysplasia. Acta Oto-Laryngologica Case Reports, 2018, 3, 5-10.	0.2	3
111	HTLV-1 myelopathy after renal transplant and antiviral prophylaxis: the need for screening. Journal of NeuroVirology, 2018, 24, 523-525.	2.1	21
112	Migraine is common in patients with sarcoidosis. Cephalalgia, 2018, 38, 2079-2082.	3.9	5
113	Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy. Neurotherapeutics, 2018, 15, 304-312.	4.4	76
114	Transcranial Magnetic Stimulation for Migraine Prevention in Adolescents: A Pilot Openâ€Label Study. Headache, 2018, 58, 724-731.	3.9	35
115	Cluster headache and the trigeminal-autonomic reflex: Driving or being driven?. Cephalalgia, 2018, 38, 1415-1417.	3.9	16
116	Comparative effects of traditional Chinese and Western migraine medicines in an animal model of nociceptive trigeminovascular activation. Cephalalgia, 2018, 38, 1215-1224.	3.9	19
117	Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia, 2018, 38, 959-969.	3.9	153
118	Visual snow syndrome: what we know so far. Current Opinion in Neurology, 2018, 31, 52-58.	3.6	63
119	Gentamicin delivery to the inner ear: Does endolymphatic hydrops matter?. PLoS ONE, 2018, 13, e0207467.	2.5	5
120	Biological insights from the premonitory symptoms of migraine. Nature Reviews Neurology, 2018, 14, 699-710.	10.1	115
121	Galcanezumab in chronic migraine. Neurology, 2018, 91, e2211-e2221.	1.1	399
122	Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet, The, 2018, 392, 2280-2287.	13.7	348
123	Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine. JAMA - Journal of the American Medical Association, 2018, 319, 1999.	7.4	379
124	Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Membersâ€™ View in anAIPMutation-Positive Family. International Journal of Endocrinology, 2018, 2018, 1-15.	1.5	9
125	Recent advances in headache neuroimaging. Current Opinion in Neurology, 2018, 31, 379-385.	3.6	44
126	Mathematical Methods for Measuring the Visually Enhanced Vestibuloâ€"Ocular Reflex and Preliminary Results from Healthy Subjects and Patient Groups. Frontiers in Neurology, 2018, 9, 69.	2.4	19

#	Article	IF	Citations
127	The Gain-Time Constant Product Quantifies Total Vestibular Output in Bilateral Vestibular Loss. Frontiers in Neurology, 2018, 9, 396.	2.4	6
128	Cluster Headache and Calcitonin Gene-Related Peptideâ€"More on Quantum Therapeutics in Headache Medicine. JAMA Neurology, 2018, 75, 1179.	9.0	6
129	Treatment of disabling headache with greater occipital nerve injections in a large population of childhood and adolescent patients: a service evaluation. Journal of Headache and Pain, 2018, 19, 5.	6.0	35
130	Instrumental head impulse test changes after intratympanic gentamicin for unilateral definite MÃ©niÃ¨reâ€™s disease: A systematic review and meta-analysis. Auris Nasus Larynx, 2018, 45, 943-951.	1.2	9
131	Headache and Ophthalmoparesis: Case Report of an â€œAtypicalâ€•Incomplete Millerâ€"Fisher Syndrome. Headache, 2018, 58, 746-749.	3.9	4
132	Gray matter volume modifications in migraine. Neurology, 2018, 91, e280-e292.	1.1	49
133	Comment: Noninvasive neurostimulation for migraine should be part of the general neurologist's therapeutic armamentarium. Neurology, 2018, 91, 167-167.	1.1	1
134	Neuroendocrine signaling modulates specific neural networks relevant to migraine. Neurobiology of Disease, 2017, 101, 16-26.	4.4	40
135	Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiological Reviews, 2017, 97, 553-622.	28.8	1,168
136	Home-Based Trials in Adolescent Migraine. JAMA Neurology, 2017, 74, 744.	9.0	25
137	Increased rate of venous thrombosis may be associated with inpatient dihydroergotamine treatment. Neurology, 2017, 89, 279-283.	1.1	12
138	An update on migraine: current understanding and future directions. Journal of Neurology, 2017, 264, 2031-2039.	3.6	106
139	An Update on Nonâ€Pharmacological Neuromodulation for the Acute and Preventive Treatment of Migraine. Headache, 2017, 57, 685-691.	3.9	48
140	Calcitonin gene-related peptide and pain: a systematic review. Journal of Headache and Pain, 2017, 18, 34.	6.0	161
141	Erenumab (AMG 334) in episodic migraine. Neurology, 2017, 89, 1237-1243.	1.1	120
142	Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. JAMA Neurology, 2017, 74, 1266.	9.0	33
143	Fremanezumab for the Preventive Treatment of Chronic Migraine. New England Journal of Medicine, 2017, 377, 2113-2122.	27.0	573
144	A Controlled Trial of Erenumab for Episodic Migraine. New England Journal of Medicine, 2017, 377, 2123-2132.	27.0	661

#	Article	IF	Citations
145	The limits of stability in patients with unilateral vestibulopathy. Acta Oto-Laryngologica, 2017, 137, 1051-1056.	0.9	7
146	Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?. Current Treatment Options in Neurology, 2017, 19, 27.	1.8	119
147	Occipital headaches and neuroimaging in children. Neurology, 2017, 89, 469-474.	1.1	25
148	Acute vestibular syndrome with down-beat nystagmus as a sole clinical presentation in AICA transient ischemic attack with an uncommon clinical course. Acta Oto-Laryngologica Case Reports, 2017, 2, 131-136.	0.2	1
149	Vestibulo-Ocular Reflex Stabilization after Vestibular Schwannoma Surgery: A Story Told by Saccades. Frontiers in Neurology, 2017, 8, 15.	2.4	26
150	Diagnostic Bedside Vestibuloocular Reflex Evaluation in the Setting of a False Negative Fistula Test in Cholesteatoma of the Middle Ear. Case Reports in Otolaryngology, 2017, 2017, 1-5.	0.2	7
151	The Role of Melatonin in the Treatment of Primary Headache Disorders. Headache, 2016, 56, 1257-1266.	3.9	74
152	The migraine postdrome. Neurology, 2016, 87, 309-313.	1.1	134
153	The utility of radioisotope cisternography in low CSF/volume syndromes compared to myelography. Cephalalgia, 2016, 36, 1291-1295.	3.9	13
154	Headache. Seminars in Neurology, 2016, 36, 442-448.	1.4	1
155	Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache. Neurology, 2016, 87, 2522-2526.	1.1	10
156	Aprepitant for the management of nausea with inpatient IV dihydroergotamine. Neurology, 2016, 87, 1613-1616.	1.1	11
157	Chronic migraine headache prevention with noninvasive vagus nerve stimulation. Neurology, 2016, 87, 529-538.	1.1	191
158	TEV-48125 for the preventive treatment of chronic migraine. Neurology, 2016, 87, 41-48.	1.1	84
159	Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine. Pain, 2016, 157, 1666-1673.	4.2	37
160	Ictal lack of binding to brain parenchyma suggests integrity of the bloodâ€“brain barrier for¹¹C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain, 2016, 139, 1994-2001.	7.6	66
161	Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain, 2016, 139, 2002-2014.	7.6	105
162	Predictors of Triptan Response in Pediatric Migraine. Pediatric Neurology, 2016, 58, 37-40.	2.1	14

#	Article	IF	Citations
163	Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2016, 15, 382-390.	10.2	312
164	Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome. Neurology, 2016, 86, 856-859.	1.1	17
165	Therapeutic illusion: another frontier in MÃ©niÃ¨reâ€™s disease. Annals of Translational Medicine, 2016, 4, S63-S63.	1.7	0
166	A Puzzle of Vestibular Physiology in a Menereâ€™s Disease Acute Attack. Case Reports in Otolaryngology, 2015, 2015, 1-5.	0.2	13
167	Putting migraine to sleep: Rexants as a preventive strategy. Cephalalgia, 2015, 35, 377-378.	3.9	6
168	Reduced efficacy of sumatriptan in migraine with aura vs without aura. Neurology, 2015, 84, 1880-1885.	1.1	28
169	Is migraine a risk factor for pediatric stroke?. Cephalalgia, 2015, 35, 1252-1260.	3.9	41
170	Initial use of a novel noninvasive vagus nerve stimulator for cluster headache treatment. Neurology, 2015, 84, 1249-1253.	1.1	120
171	The anterior insula shows heightened interictal intrinsic connectivity in migraine without aura. Neurology, 2015, 84, 1043-1050.	1.1	63
172	Single intratympanic gentamicin injection in <scp>M</scp>Ã©niÃ¨re's disease: <scp>VOR</scp> change and prognostic usefulness. Laryngoscope, 2015, 125, 1915-1920.	2.0	27
173	Morphological Abnormalities of Thalamic Subnuclei in Migraine: A Multicenter MRI Study at 3 Tesla. Journal of Neuroscience, 2015, 35, 13800-13806.	3.6	62
174	Incredible progress for an era of better migraine care. Nature Reviews Neurology, 2015, 11, 621-622.	10.1	17
175	The Premonitory Phase of Migraine â€“ What Can We Learn From It?. Headache, 2015, 55, 609-620.	3.9	61
176	Neuronal PAC ₁ receptors mediate delayed activation and sensitization of trigeminocervical neurons: Relevance to migraine. Science Translational Medicine, 2015, 7, 308ra157.	12.4	109
177	The effect of intra-tympanic dexamethasone on the vestibular function in patients with recurrent vertigo. Acta Oto-Laryngologica, 2015, 135, 1253-1258.	0.9	1
178	Long-term follow-up of late onset vestibular complaints in patients with cochlear implant. Acta Oto-Laryngologica, 2015, 135, 1245-1252.	0.9	9
179	The relationship between migraine and infant colic: A systematic review and meta-analysis. Cephalalgia, 2015, 35, 63-72.	3.9	40
180	Evidence for orexinergic mechanisms in migraine. Neurobiology of Disease, 2015, 74, 137-143.	4.4	71

#	Article	IF	Citations
181	BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia, 2014, 34, 114-125.	3.9	241
182	Stress and migraine: Something expected, something unexpected. Neurology, 2014, 82, 1388-1389.	1.1	10
183	Migraineâ€Like Features in Cluster Headache. Headache, 2014, 54, 555-555.	3.9	1
184	Differential trigeminovascular nociceptive responses in the thalamus in the familial hemiplegic migraine 1 knock-in mouse: A Fos protein study. Neurobiology of Disease, 2014, 64, 1-7.	4.4	21
185	Recent onset disequilibrium mimicking acute vestibulopathy in early multiple sclerosis. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2014, 35, 529-534.	1.3	7
186	Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurology, The, 2014, 13, 1100-1107.	10.2	333
187	Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurology, The, 2014, 13, 885-892.	10.2	332
188	Vestibulo-ocular reflex in patients with superior semicircular canal benign paroxysmal positional vertigo (BPPV). Acta Oto-Laryngologica, 2014, 134, 485-490.	0.9	11
189	Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology, 2014, 83, 958-966.	1.1	235
190	Hemicrania continua- building on experience and clinical science. Journal of Headache and Pain, 2014, 15, 9.	6.0	5
191	A multicenter observational study on the role of comorbidities in the recurrent episodes of benign paroxysmal positional vertigo. Auris Nasus Larynx, 2014, 41, 31-36.	1.2	101
192	Therapeutic prospects for migraine: Can paradise be regained?. Annals of Neurology, 2013, 74, 423-434.	5.3	22
193	Autonomic nervous system control of the cerebral circulation. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 117, 193-201.	1.8	67
194	Migraine and multiple sclerosis: Epidemiology and approach to treatment. Multiple Sclerosis and Related Disorders, 2013, 2, 73-79.	2.0	22
195	All that is obvious is not clear: What is the origin of throbbing pain in migraine?. Pain, 2013, 154, 970-971.	4.2	3
196	Analysis of occipital nerve stimulation in studies of chronic migraine and broader implications of social media in clinical trials. Cephalalgia, 2013, 33, 214-215.	3.9	17
197	Author's reply on Pathophysiology of migraine. Annals of Indian Academy of Neurology, 2013, 16, 456-7.	0.5	1
198	Pathophysiology of migraine. Annals of Indian Academy of Neurology, 2012, 15, 15.	0.5	112

#	Article	IF	Citations
199	Trigeminal Autonomic Cephalalgias. CONTINUUM Lifelong Learning in Neurology, 2012, 18, 883-895.	0.8	22
200	Before the headache. Neurology, 2012, 79, 1392-1396.	1.1	62
201	A translational in vivo model of trigeminal autonomic cephalalgias: therapeutic characterization. Brain, 2012, 135, 3664-3675.	7.6	82
202	Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia, 2011, 31, 712-722.	3.9	251
203	New Daily Persistent Headache: A Syndrome Not a Discrete Disorder. Headache, 2011, 51, 650-653.	3.9	36
204	Trigeminal Neuropathic Pain in a Patient With Progressive Facial Hemiatrophy (Parry-Romberg) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542	4.5	21
205	A potential nitrergic mechanism of action for indomethacin, but not of other COX inhibitors: relevance to indomethacin-sensitive headaches. Journal of Headache and Pain, 2010, 11, 477-483.	6.0	66
206	Current practice and future directions in the prevention and acute management of migraine. Lancet Neurology, The, 2010, 9, 285-298.	10.2	203
207	Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurology, The, 2010, 9, 373-380.	10.2	413
208	Auditory and Vestibular Assessment of Patients with MÃ©niÃ¨reâ€™s Disease Who Suffer Tumarkin Attacks. Audiology and Neuro-Otology, 2010, 15, 399-406.	1.3	24
209	Hemicrania continua: a clinical study of 39 patients with diagnostic implications. Brain, 2010, 133, 1973-1986.	7.6	148
210	Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain, 2010, 133, 2540-2548.	7.6	99
211	Trigeminal Autonomic Cephalalgias: Paroxysmal Hemicrania, SUNCT/SUNA, and Hemicrania Continua. Seminars in Neurology, 2010, 30, 186-191.	1.4	85
212	CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews Neurology, 2010, 6, 573-582.	10.1	418
213	The vascular theory of migraineâ€"a great story wrecked by the facts. Brain, 2009, 132, 6-7.	7.6	151
214	Neurons of the Dopaminergic/Calcitonin Gene-Related Peptide A11 Cell Group Modulate Neuronal Firing in the Trigeminocervical Complex: An Electrophysiological and Immunohistochemical Study. Journal of Neuroscience, 2009, 29, 12532-12541.	3.6	105
215	Foreword. Cephalalgia, 2009, 29, v-vi.	3.9	0
216	Pathophysiology of Migraine. Neurologic Clinics, 2009, 27, 335-360.	1.8	123

#	Article	IF	Citations
217	Occipital Nerve Stimulation for Headache: Mechanisms and Efficacy. Headache, 2008, 48, 313-318.	3.9	68
218	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. Headache, 2008, 48, 799-804.	3.9	17
219	Refractory Migraine and Chronic Migraine: Pathophysiological Mechanisms. Headache, 2008, 48, 1399-1405.	3.9	19
220	Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain, 2008, 131, 1142-1155.	7.6	160
221	Migraine in pregnancy. BMJ: British Medical Journal, 2008, 336, 1502-1504.	2.3	237
222	Trigeminal autonomic cephalalgias: diagnostic and therapeutic developments. Current Opinion in Neurology, 2008, 21, 323-330.	3.6	70
223	Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends in Molecular Medicine, 2007, 13, 39-44.	6.7	250
224	Neurostimulation in primary headache syndromes. Expert Review of Neurotherapeutics, 2007, 7, 1785-1789.	2.8	41
225	Emerging therapies for migraine. Nature Clinical Practice Neurology, 2007, 3, 610-619.	2.5	50
226	Trigeminal autonomic cephalalgias: Diagnosis and treatment. Current Neurology and Neuroscience Reports, 2007, 7, 117-125.	4.2	42
227	Squeezing life into botulinum toxin A in migraine: Imploding versus Exploding Pain. Pain, 2006, 125, 206-207.	4.2	6
228	Zolmitriptan Intranasal: A Review of the Pharmacokinetics and Clinical Efficacy. Headache, 2006, 46, 138-149.	3.9	48
229	Headache: a good year for research. Lancet Neurology, The, 2006, 5, 5-6.	10.2	1
230	Posterior hypothalamic activation in paroxysmal hemicrania. Annals of Neurology, 2006, 59, 535-545.	5.3	190
231	Migraine: emerging treatment options for preventive and acute attack therapy. Expert Opinion on Emerging Drugs, 2006, 11, 419-427.	2.4	22
232	Analysis of the vestibulo-ocular reflex time constant in patients with benign recurrent vertigo associated with head-shaking nystagmus. Acta Oto-Laryngologica, 2006, 126, 358-363.	0.9	1
233	The Migrainous Brain: What You See Is Not All You Get?. PLoS Medicine, 2006, 3, e404.	8.4	11
234	Recent advances in the diagnosis and management of migraine. BMJ: British Medical Journal, 2006, 332, 25-29.	2.3	55

#	Article	IF	Citations
235	Migraine Pathophysiology. Headache, 2005, 45, S14-24.	3.9	139
236	Can we Develop Neurally Acting Drugs for the Treatment of Migraine?. Nature Reviews Drug Discovery, 2005, 4, 741-750.	46.4	64
237	Advances in the understanding of headache. British Medical Bulletin, 2005, 73-74, 83-92.	6.9	20
238	Another migraine gene. Lancet, The, 2005, 366, 345-346.	13.7	15
239	Posterior Hypothalamic and Brainstem Activation in Hemicrania Continua. Headache, 2004, 44, 747-761.	3.9	244
240	Basic Science: Prejunctional and Presynaptic Trigeminovascular Targets: What Preclinical Evidence Is There?. Headache Currents: A Journal for Recent Advances in Headache and Facial Pain, 2004, 1, 1-6.	0.7	4
241	Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. British Journal of Pharmacology, 2004, 142, 1171-1181.	5.4	274
242	The future of headache. Journal of Neurology, 2004, 251, 630-636.	3.6	1
243	Post-triptan era for the treatment of acute migraine. Current Pain and Headache Reports, 2004, 8, 393-398.	2.9	21
244	Calcitonin Geneâ€"Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. New England Journal of Medicine, 2004, 350, 1104-1110.	27.0	1,118
245	The trigeminocervical complex and migraine: Current concepts and synthesis. Current Pain and Headache Reports, 2003, 7, 371-376.	2.9	244
246	Hypnic headache. Neurology, 2003, 60, 905-909.	1.1	207
247	Headache (chronic tension type). Clinical Evidence, 2003, , 1432-40.	0.2	0
248	Headache (chronic tension-type). Clinical Evidence, 2003, , 1538-46.	0.2	0
249	Low CSF Volume (Pressure) Headache. Practical Neurology, 2002, 2, 192-197.	1.1	5
250	Migraine â€" Current Understanding and Treatment. New England Journal of Medicine, 2002, 346, 257-270.	27.0	1,692
251	New directions in migraine research. Journal of Clinical Neuroscience, 2002, 9, 368-373.	1.5	13
252	The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. European Journal of Pharmacology, 2002, 452, 223-228.	3.5	61

#	Article	IF	Citations
253	Pathophysiology of cluster headache: a trigeminal autonomic cephalgia. Lancet Neurology, The, 2002, 1, 251-257.	10.2	416
254	Migraine Management: Contrasting Patient Preferences With Current Clinical End Points: Introduction. Headache, 2002, 42, 1-2.	3.9	3
255	New daily persistent headache. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72 Suppl 2, ii6-ii9.	1.9	30
256	Chronic daily headache. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72 Suppl 2, ii2-ii5.	1.9	7
257	Hypothalamic involvement and activation in cluster headache. Current Pain and Headache Reports, 2001, 5, 60-66.	2.9	51
258	Effect of Rizatriptan and Other Triptans on the Nausea Symptom of Migraine: A Post Hoc Analysis. Headache, 2001, 41, 754-763.	3.9	38
259	Fos expression in the midbrain periaqueductal grey after trigeminovascular stimulation. Journal of Anatomy, 2001, 198, 29-35.	1.5	88
260	Neuroimaging in headache. Microscopy Research and Technique, 2001, 53, 179-187.	2.2	29
261	GABA receptors modulate trigeminovascular nociceptive neurotransmission in the trigeminocervical complex. British Journal of Pharmacology, 2001, 134, 896-904.	5.4	36
262	Migraine: Selecting Treatments now and Making Requests for the Future?. Current Medical Research and Opinion, 2001, 17, s98-99.	1.9	2
263	The pharmacology of headache. Progress in Neurobiology, 2000, 62, 509-525.	5.7	228
264	Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. Journal of Anatomy, 1999, 194, 579-588.	1.5	122
265	Helospectin-Like Peptides: Immunochemical Localization and Effects on Isolated Cerebral Arteries and on Local Cerebral Blood Flow in the Cat. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 61-67.	4.3	12
266	The Trigeminovascular System in Humans: Pathophysiologic Implications for Primary Headache Syndromes of the Neural Influences on the Cerebral Circulation. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 115-127.	4.3	521
267	Advances in the Pharmacotherapy of Migraine. Drugs in R and D, 1999, 2, 361-374.	2.2	20
268	Differential effects of low dose CP122,288 and eletriptan on Fos expression due to stimulation of the superior sagittal sinus in cat â˜†. Pain, 1999, 82, 15-22.	4.2	57
269	The Scientific Basis of Medication Choice in Symptomatic Migraine Treatment. Canadian Journal of Neurological Sciences, 1999, 26, 20-26.	0.5	36
270	Stimulation of the middle meningeal artery leads to Fos expression in the trigeminocervical nucleus: a comparative study of monkey and cat. American Journal of Anatomy, 1999, 194, 579-588.	1.0	2

#	Article	IF	Citations
271	Neuropeptides in headache. European Journal of Neurology, 1998, 5, 329-341.	3.3	84
272	Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. European Journal of Neurology, 1998, 5, 535-543.	3.3	52
273	Hypothalamic activation in cluster headache attacks. Lancet, The, 1998, 352, 275-278.	13.7	1,092
274	Serotonin 5-HT1B/1D Receptor Agonists in Migraine. CNS Drugs, 1998, 10, 271-286.	5.9	78
275	Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT1B/1D) receptors. British Journal of Pharmacology, 1997, 122, 918-922.	5.4	106
276	The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a câ€fos immunocytochemical study. Journal of Anatomy, 1997, 190, 367-375.	1.5	214
277	Fortnightly Review: Diagnosis and management of migraine. BMJ: British Medical Journal, 1996, 312, 1279-1283.	2.3	66
278	Peripheral and Central Trigeminovascular Activation in Cat is Blocked by the Serotonin (5HT)-I D Receptor Agonist 311C90. Headache, 1994, 34, 394-399.	3.9	170
279	The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Annals of Neurology, 1993, 33, 48-56.	5.3	1,021
280	Intravenous Acetylsalicylic Acid Inhibits Central Trigeminal Neurons in the Dorsal Horn of the Upper Cervical Spinal Cord in the Cat. Headache, 1993, 33, 541-544.	3.9	81
281	Expression of c-Fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Research, 1993, 629, 95-102.	2.2	239
282	The distribution of trigeminovascular afferents in the nonhuman primate brain Macaca nemestrina: a c-fos immunocytochemical study. , 0, .		3